Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Feb 27, 2022; 14(2): 143-160
Published online Feb 27, 2022. doi: 10.4240/wjgs.v14.i2.143
Table 1 Baseline characteristics of patients with pT1N2-3 and pT3N0 GC, n (%)
Characteristic
pT1N2-3b (n = 89)
pT3N0 (n = 370)
P value
Sex< 0.001
Male44 (49.4)269 (72.7)
Female45 (50.6)101 (27.3)
Age (yr)0.071
≤ 6058 (65.2)219 (59.2)
> 6025 (34.8)151 (40.8)
BMI (kg/m2)0.964
< 2463 (70.8)261 (70.5)
≥ 2426 (29.2)109 (29.5)
Borrmann type< 0.001
089 (100.0)0 (0.0)
10 (0.0)23 (6.2)
20 (0.0)126 (34.1)
30 (0.0)195 (52.7)
4 or 50 (0.0)26 (7.0)
Tumor diameter (mm)0.002
≤ 5074 (83.1)245 (66.2)
> 5015 (16.9)125 (33.8)
Tumor location0.007
Upper4 (4.5)53 (14.3)
Middle11 (12.4)66 (17.8)
Lower74 (83.1)243 (65.7)
Total0 (0.0)8 (2.2)
Gastrectomy0.001
Partial gastrectomy83 (93.3)289 (78.1)
Total gastrectomy6 (6.7)81 (21.9)
Histological type0.043
Differentiated32 (36.0)177 (47.8)
Undifferentiated57 (64.0)193 (52.2)
pT stage< 0.001
T1a18 (20.2)0 (0.0)
T1b71 (79.8)0 (0.0)
T30 (0.0)370 (100.0)
pN stage< 0.001
N00 (0.0)370 (100.0)
N270 (78.7)0 (0.0)
N3a18 (20.2)0 (0.0)
N3b1 (1.1)0 (0.0)
Vascular infiltration0.021
No64 (71.9)306 (82.7)
Yes25 (28.1)64 (17.3)
Nerve infiltration< 0.001
No82 (92.1)224 (60.5)
Yes7 (7.9)146 (39.5)
Postoperative chemotherapy< 0.001
Yes52 (58.4)114 (30.8)
No37 (41.6)256 (69.2)